Strategy & Commercialization (3)

Challenge On behalf of an established Alacrita client, a publicly traded clinical stage biotechnology company with a cell therapy platform technology, we assessed the potential of a novel...

Challenge A clinical-stage biotech company had an ongoing Phase 1 program exploring a combination therapy in multiple cancer types. The company wished to validate the addition of cholangiocarcinoma...

Challenge A UK-based oncology drug development company sought to understand the potential value of a small molecule product in metastatic breast cancer (MBC). Alacrita was commissioned to produce an...

Challenge A clinical stage microbiome company developing a microbiome therapeutic for the treatment of recurrent C. Difficile infection (rCDI) was looking to identify promising opportunities for new...

Challenge An early-stage, venture-backed, private biotechnology company developing a novel multi-gene therapy approach to addressing chronic, age-related diseases requested an opportunity mapping...

Challenge: A company with a microbiome-conditioning product was seeking the optimum strategic positioning to enable a trade sale to a major company. Unusually for a venture in this field, the company...

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...

Challenge: Our client was a leading UK research institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita...

Challenge: A new GMP facility for the production of investigational cell and gene therapies needed regulatory, market and technical advice before committing to a capacity expansion.

Challenge An established European pharma company needed an opportunity assessment for a reformulation of a marketed biologic.

Challenge: A university commercialization institute asked Alacrita to review its technology for 3D printed, customised silicone medical products. The main task was to determine the prospective value...